Chromadex Corp (NASDAQ: CDXC) has experienced a rise in its stock price by 9.51 compared to its previous closing price of 2.63. However, the company has seen a gain of 5.11% in its stock price over the last five trading days. zacks.com reported 2024-08-07 that ChromaDex (CDXC) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.03 per share a year ago.
Is It Worth Investing in Chromadex Corp (NASDAQ: CDXC) Right Now?
CDXC has 36-month beta value of 1.86. Analysts have mixed views on the stock, with 1 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CDXC is 48.51M, and currently, short sellers hold a 6.49% ratio of that float. The average trading volume of CDXC on August 09, 2024 was 389.56K shares.
CDXC’s Market Performance
The stock of Chromadex Corp (CDXC) has seen a 5.11% increase in the past week, with a 9.51% rise in the past month, and a -24.80% fall in the past quarter. The volatility ratio for the week is 9.41%, and the volatility levels for the past 30 days are at 9.01% for CDXC. The simple moving average for the past 20 days is -0.37% for CDXC’s stock, with a 23.00% simple moving average for the past 200 days.
Analysts’ Opinion of CDXC
B. Riley Securities, on the other hand, stated in their research note that they expect to see CDXC reach a price target of $2.40, previously predicting the price at $6. The rating they have provided for CDXC stocks is “Neutral” according to the report published on August 11th, 2022.
ROTH Capital gave a rating of “Buy” to CDXC, setting the target price at $7 in the report published on March 08th of the previous year.
CDXC Trading at 1.89% from the 50-Day Moving Average
After a stumble in the market that brought CDXC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -38.06% of loss for the given period.
Volatility was left at 9.01%, however, over the last 30 days, the volatility rate increased by 9.41%. Over the last 50 days, in opposition, the stock is trading +3.97% upper at present.
During the last 5 trading sessions, CDXC rose by +5.11%, which changed the moving average for the period of 200-days by +123.26% in comparison to the 20-day moving average, which settled at $2.89. In addition, Chromadex Corp saw 101.40% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CDXC starting from Gerber Brianna, who purchase 5,000 shares at the price of $1.41 back on Dec 01 ’23. After this action, Gerber Brianna now owns 27,436 shares of Chromadex Corp, valued at $7,050 using the latest closing price.
Stock Fundamentals for CDXC
Current profitability levels for the company are sitting at:
- -0.01 for the present operating margin
- 0.55 for the gross margin
The net margin for Chromadex Corp stands at -0.01. The total capital return value is set at -0.03. Equity return is now at value -4.67, with -2.52 for asset returns.
Based on Chromadex Corp (CDXC), the company’s capital structure generated 0.09 points at debt to capital in total, while cash flow to debt ratio is standing at 0.4. The debt to equity ratio resting at 0.1. The interest coverage ratio of the stock is 6.29.
Currently, EBITDA for the company is -0.19 million with net debt to EBITDA at -2751.22. When we switch over and look at the enterprise to sales, we see a ratio of 2.04. The receivables turnover for the company is 12.1for trailing twelve months and the total asset turnover is 1.75. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.76.
Conclusion
To put it simply, Chromadex Corp (CDXC) has had a better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
